Initiation or maintenance of beta-blocker therapy in patients hospitalized for acute heart failure

International Journal of Clinical Pharmacy

Volumn 38, Issue 4, 2016, Pages 802-807

  Passos, Luiz Carlos ^a   Oliveira, Márcio Galvão ^a   Duraes, Andre Rodrigues ^b   Trindade, Thiago Moreira ^a   Barbosa, Andréa Cristina Costa ^c  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Ana Nery Hospital   (Brazil)

^c Bahia Foundation of Cardiology   (Brazil)

Author keywords

Acute heart failure; Beta blockers; Brazil

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACUTE HEART FAILURE; ADULT; ARTICLE; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ELECTRONIC MEDICAL RECORD; FEMALE; FORWARD HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPOTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LENGTH OF STAY; LIFE EXPECTANCY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHOCK; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; AGED; COMPARATIVE STUDY; HEART FAILURE; MIDDLE AGED; MORTALITY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84965022427     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-016-0265-x     Document Type: Article

References (24)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.
2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2013;128(16):1810–52.
3. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805.
4. Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, et al. B-convinced: beta-blocker continuation vs. interruption in patients with Congestive heart failure hospitalized for a decompensation episode. Eur Heart J. 2009;30(18):2186–92.
5. Kukin ML, Freudenberger RS, Mannino MM, Kalman J, Steinmetz M, Buchholz-Varley C, et al. Short-term and long-term hemodynamic and clinical effects of metoprolol alone and combined with amlodipine in patients with chronic heart failure. Am Heart J. 1999;138(2 Pt 1):261–8.
6. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25(5):1154–61.
7. Montera MW, Almeida DR, Tinoco EM, Rocha RM, Moura LZ, Rea-Neto A, et al. II Diretriz Brasileira de Insuficiência Cardiaca Aguda. Arq Bras Cardiol. 2009;93(3):2–65.
8. Montera MW, Pereira SB, Colafranceschi AS, Almeida DRd, Tinoco EM, Rocha RM, et al. Summary of the II Brazilian guideline update on acute heart failure 2009/2011. Arq Bras Cardiol. 2012;98(5):375–83.
9. Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43(1):61–7.
10. Patel P, White DL, Deswal A. Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. Am Heart J. 2007;153(4):515–22.
11. Krum H, Hill J, Fruhwald F, Sharpe C, Abraham G, Zhu JR, et al. Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study. Eur J Heart Fail. 2006;8(3):302–7.
12. Collins SP, Pang PS, Lindsell CJ, Kyriacou DN, Storrow AB, Hollander JE, et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail. 2010;12(11):1253–60.
13. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European society of cardiology guidelines? Evidence from 12,440 patients of the esc heart failure long-term registry. Eur J Heart Fail. 2013;15(10):1173–84.
14. Tarantini L, Cioffi G, Opasich C, Di Lenarda A, Pulignano G, Del Sindaco D, et al. Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure. Ital Heart J. 2004;5(6):441–9.
15. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar J, Cohen-Solal A, et al. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464–74.
16. Packer M, Bristow M, Cohn J, Colucci W, Fowler M, Gilbert E, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group. N Engl J Med. 1996;334(21):1349–55.
17. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand heart failure research collaborative group. Circulation. 1995;92(2):212–218
18. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in dilated cardiomyopathy (MDC) trial study group. Lancet. 1993;342(8885):1441–6.
19. Eichhorn EJ. The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am J Med. 1992;92(5):527–38.
20. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997;79(6):794–8.
21. Dharmarajan K, Masoudi FA, Spertus JA, Li SX, Krumholz HM. Contraindicated initiation of beta-blocker therapy in patients hospitalized for heart failure. JAMA Intern Med. 2013;173(16):1547–9.
22. Atwater BD, Dai D, Allen-Lapointe NM, Al-Khatib SM, Zimmer LO, Sanders GD, et al. Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. Am Heart J. 2012;164(5):750–755.e1.
23. Orso F, Baldasseroni S, Fabbri G, Gonzini L, Lucci D, D’Ambrosi C, et al. Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. Eur J Heart Fail. 2009;11(1):77–84.
24. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008;52(3):190–9.